Coriell Life Sciences (CLS) is a cutting-edge for-profit venture focused on empowering physicians to apply genetic analyses at point-of-care.
CLS is a spin-off of the internationally-renowned Coriell Institute for Medical Research, a non-profit biomedical research institution dedicated to studying the human genome to improve the lives of healthcare consumers. The organization leverages the framework of the Coriell Personalized Medicine Collaborative, an innovative research study that brings together more than 7,000 study participants, physicians, scientists, ethicists, genetic counselors and information technologists.
CLS has developed a proprietary system for securely storing sequenced genetic data, constructed an interpretation service designed to more accurately determine drug efficacy, and facilitated a seamless exchange between healthcare providers, patients and physicians.
Three core products – GeneVault, GeneExchange, and GeneDose – integrate genomic medicine into clinical care while managing the breadth of information that is obtained through genomic sequencing. This ecosystem allows healthcare providers, patients and payors to take advantage of the available sequencing technology while carving out and interpreting only that data needed for immediate use and securely storing the data in the GeneVault for future interpretation.
Much of the essential CLS infrastructure is powered by IBM. The tech giant has contributed resources for software development, technical support, and served as a consultant on the challenge of storing the massive datasets generated by genetic sequencing.
Coriell Life Sciences was recently named the 2014 IBM Global Entrepreneur of the Year and recognized as the world's top start-up organization.